E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
E.1.1.1 | Medical condition in easily understood language |
Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036046 |
E.1.2 | Term | Polycystic kidney, autosomal dominant |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate that bosutinib reduces the rate of kidney enlargement in subjects with
autosomal dominant polycystic kidney disease (ADPKD) entering the study with total
kidney volume (TKV) ≥750 cc and eGFR ≥60 mL/min/1.73m2.
To identify a safe and efficacious dose of bosutinib to be utilized for subsequent
studies. |
|
E.2.2 | Secondary objectives of the trial |
To investigate the effect of treatment with bosutinib on renal function compared with placebo.
To determine the time to first occurrence (or worsening) of clinical measures of disease activity.
To evaluate the plasma PK of bosutinib.
To evaluate the effect of treatment with bosutinib on subject-reported, disease specific quality of life compared with placebo.
To investigate the progression of eGFR over the course of the study |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
2. Males and females, aged ≥18 years to 50 years at the time of consent.
3. Documented diagnosis of ADPKD by renal ultrasound cyst criteria based on the Unified Criteria for Ultrasonographic Diagnosis of ADPKD. A family history of ADPKD is not required to support diagnosis by ultrasound criteria. Alternatively, the diagnosis of ADPKD may be based on PKD 1 or PKD 2 genotype findings as documented in the medical record.
4. Total kidney volume ≥750 cc, as measured by centrally evaluated MRI.
5. Left ventricular ejection fraction by echocardiogram or MUGA ≥50% at screening.
6. All women of childbearing potential must have two negative pregnancy test results before administration of study drug. Women of childbearing potential must agree to use two highly effective methods of contraception as described in the protocol for at least 14 days prior to the first dose of study medication and continue until 28 days after dosing. A subject is of childbearing potential if, in the opinion of the investigator, she is biologically capable of having children and is sexually active.
7. Men willing to use two highly effective methods of contraception as described in the protocol throughout the active treatment phase of the study and for 28 days after the last dose of study drug. Any pregnancy that occurs in the female partner of a male subject in the study must be reported if it occurs at any time during the active treatment phase of the study or for 28 days after the last dose of study drug.
8. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. |
|
E.4 | Principal exclusion criteria |
Subjects presenting with any of the following will not be included in the study:
1. Weight <40 kg or >125 kg.
2. Women who are pregnant or breastfeeding or women who intend to become pregnant in the next two years.
3. Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 for primary treatment population. Subjects with moderate renal impairment (defined as 30 mL/min/1.73m2 ≤ eGFR ≤50mL/min/1.73m2) are excluded (from enrollment in an exploratory population) until results from a separate renal impairment PK study (study B1871020) demonstrate no substantial impact of renal impairment on bosutinib PK. Subjects with an eGFR<30 mL/min/1.73m2 will be excluded.
4. Abnormal urinalysis showing cellular casts.
5. Biopsy proven renal disease other than ADPKD.
6. Chronic back and/or flank pain requiring daily or near daily pain medication over the preceding month.
7. Documented renal vascular disease.
8. Documented systemic illness with renal involvement.
9. Creatine supplements within 3 months of the baseline visit.
10. Uncontrolled hypertension (defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg).
11. Uncontrolled diabetes mellitus as evidenced by screening assessments and/or recent medical record.
12. Medical history or diagnosis of immunodeficiency.
13. Autoimmune disease not in remission or requiring ongoing treatment with immunosuppressive medication.
14. Increased ALT and/or AST >2.5 x the upper limit of normal.
15. Total bilirubin >2 x the upper limit of normal (unless associated with Gilbert’s syndrome).
16. Grade 2 or higher abnormalities of serum sodium [sodium >150 or <130 mmol/l].
17. Uncorrected hypomagnesemia or hypokalemia [serum magnesium or serum potassium < lower limit of normal].
18. Grade 2 or higher elevation of serum potassium or serum magnesium [serum potassium >5.5 or serum magnesium >3.0 mg/dl (or >1.23 mmol/l)].
19. Hemoglobin <9.0 gm/dl.
20. Platelet count <100,000/microliter.
21. Congenital absence of a kidney or prior surgical resection of a kidney for any reason.
22. Clinically significant or unstable cardiac disease (eg, unstable angina, recent myocardial infarction, clinically significant arrhythmia requiring treatment, uncontrolled congestive heart failure, etc).
23. Subjects with any pre dose corrected QT interval (QTc) ≥450 msec based on any one of the machine read tracing using Fridericia’s formulae obtained at screening. Any decision to retest a subject must first be discussed with the Pfizer Medical Monitor. If a repeat QTcF interval obtained pre-dose is ≥450 msec, the subject is excluded from enrollment.
24. History of prolonged QTc interval or additional risk factors for Torsade de Pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).
25. History or evidence of infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
26. Past or present malignancy (with the exception of adequately treated, localized basal cell or squamous cell carcinoma of the skin).
27. Use of any investigational drug or investigational biologic compound within 4 weeks prior to the screening visit or during the screening period.
28. Participation in any interventional studies within 4 weeks prior to the screening visit and/or during study participation.
29. Any previous exposure to the bosutinib study drug, including previous participation in a bosutinib clinical study, or receipt of other therapies intended to modify the progression of polycystic kidney disease (supportive care measures excepted).
30. Contraindication(s) to undergoing magnetic resonance imaging (MRI).
31. Mental illness that could interfere with the subject’s ability to comply with the protocol.
32. Ongoing treatment with Digoxin.
33. Ongoing treatment with strong P Glycoprotein inhibitors or inducers
34. Ongoing treatment with strong CYP3A inhibitors.
35. Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the study.
36. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Annualized rate (%) of kidney enlargement relative to placebo.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• The following clinical parameters to assess disease progression will be evaluated:
• Rate of decline of estimated Glomerular Filtration Rate (eGFR) relative to placebo will be investigated.
• Time to first occurrence or worsening of hypertension, defined as the need for increased dose of or need for additional anti hypertensive medication.
• Time to first occurrence or worsening of back and/or flank pain.
• Time to first occurrence of gross hematuria.
• Time to first occurrence of proteinuria.
• Onset of end stage renal disease requiring dialysis ≥56 days.
• Renal function evaluations to include blood urea nitrogen and serum creatinine.
• Pharmcokinetic parameters of bosutinib including Cmax, tmax, AUCtau, Cmin, Clearance, Vz/F, t1/2, and R.
• Quality of Life measured by the Kidney Disease Quality of Life (KDQoL 36) questionnaire. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 37 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Bulgaria |
Canada |
Czech Republic |
Hungary |
Italy |
Japan |
Korea, Democratic People's Republic of |
Lithuania |
Moldova, Republic of |
Poland |
Romania |
Slovakia |
Spain |
Sweden |
Switzerland |
Turkey |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |